期刊文献+

G250mAb修饰的肿瘤细胞靶向基因载体功能研究

Study on vector function of G250 mAb modified tumor cell target gene
下载PDF
导出
摘要 目的分析G250m Ab与聚乙烯亚胺(PEI)偶联作为肿瘤靶向基因载体系统的优越性,为肿瘤细胞靶向基因治疗提供研究基础。方法通过二硫键将G250m Ab与PEI偶联,得到修饰后的基因载体G250m Ab-PEI,利用体外转染细胞的方法研究其转基因的优越性。结果 G250m Ab-PEI转染效率明显高于单纯PEI或传统脂质体转染;其毒性也较未修饰的PEI低;对人宫颈癌细胞Hela的基因转染具有显著的靶向性,其转基因效率是肝癌细胞Hep G2(G250阴性)的2倍,而对正常血管平滑肌细胞的基因转染效率较Hela低近20倍。结论 G250m Ab-PEI是一种高效、低毒和具有靶向性的基因载体。 Objective To research and analyze the superiority of G250mAb coupling with polyethyleneimine (PEI) as a tumor-targeted gene vector to lay the foundation for targeted gene therapy of tumor cells. Methods G250mAb was coupled with PEI by the disulfide bond for obtaining the modified gene vector G250mAb-PEI. The transfected cells in vitro method was applied to study its transgenetic superiority. Results The transfection efficiency of G250mAb-PEI was significantly higher than that of pure PEI or traditional lipofectamine trasfection;its toxicity was lower than that of non-modified PEI;the gene transfection of cer-vical cancer Hela cells had significant targeting and its transfection efficiency was twice that of liver cancer cells HepG2 (G250 negative),but the transfection efficiency of normal vascular smooth muscle cells (SMC) was lower than that of Hela by nearly 20-fold. Conclusion G250mAb-PEI is a highly efficient gene vector with low cytotoxicity and targeting effect.
出处 《现代医药卫生》 2015年第12期1764-1766,1769,共4页 Journal of Modern Medicine & Health
基金 青岛市卫生科技发展计划项目(WSZD080)
关键词 HELA细胞 聚乙烯亚胺 遗传载体 肿瘤/病理学 基因 转染 G250m Ab G250mAb Hela cell Polyethyleneimine Genetic vectors Neoplasms/pathology Genes Transfection G250mAb
  • 相关文献

参考文献13

  • 1唐彬秩,秦豪杰,傅强,屈艺.重组腺相关病毒:很有潜力的基因治疗载体[J].生物化学与生物物理进展,2006,33(8):711-718. 被引量:8
  • 2Nakanishi H. Mazda O.Satoh E ,et al. Nonviral genetic transfer of Fas lig- and induced significan! growth suppression and apoptotic tumor cell death in prostate c'ancer in vivo[J]. Gene Ther, 2003,10 (5) :434-442.
  • 3谢力,李鸿钧,孙茂盛.单克隆抗体在肿瘤治疗中的应用进展[J].国际免疫学杂志,2012,35(6):445-448. 被引量:5
  • 4Su X ,Zhang L Jin L,et al. Immunotherapy with eytokine-induced killer cells in metastatic renal cell carcinoma[J]. Cancer Biother Radiopharm,2010, 25 (4) 465-470.
  • 5Mulders P. Bleumer 1,0osterwijk E. Tumor antigens and markers in renal cell carcinoma[J ]. Urol Clin North Am, 2003,30 (3) :455-465.
  • 6Duan Y,Zheng J, Han S, et al. A tumor targeted genevector modified with G250 monoelonal antibody for gene therapy[J]. J Con- trol Release, 2008,127 (2) : 173-179.
  • 7汤谷平,范辉,胡奇达.阳离子聚合物作为基因载体的研究进展[J].浙江大学学报(医学版),2012,41(6):593-598. 被引量:2
  • 8Koo H ,Jin GW, Kang H, et al. Biodegradable branched poly (ethylenimine sulfide)for gene delivery[J]. Biomaterinis, 2010,31 (5) : 988-997.
  • 9Goula D, Benoist C', Mantero S, et al. Polyethylenimine-based intravenous delivery of transgenes to mouse lung[J], Gene Ther, 2009,5 (9) : 1291-1295.
  • 10Bleumer I, Knuth A, Oosterijk E,et al. A phase II trial of chimeric mono-clonal antibody G250 for advanced renal cell carcinoma patient [J]. Br J Cancer, 2004,90 ( 5 ) : 985-990.

二级参考文献77

  • 1Hai-xia Tong,Chun-wei Lu,Ji-hong Zhang,Li Ma,Jin-hua Zhang.COMBINATION OF γ-INTERFERON WITH TRAIL AND CISPLATIN OR ETOPOSIDE INDUCES APOPTOSIS IN HUMAN NEUROBLASTOMA CELL LINE SH-SY5Y[J].Chinese Medical Sciences Journal,2007,22(1):38-43. 被引量:9
  • 2Xu D,McCarty D M,Fernandes A,et al.Delivery of small interfering RNA by self-complementary recombinantadenoassociated virus (scAAV) vector.Mol Ther,2005,11 (4):523~530
  • 3Kohli M,Rago C,Lengauer C,et al.Facile methods for generating human somatic cell gene knockouts using recombinant adenoassociated viruses.Nucleic Acids Res,2004,32 (1):e3
  • 4Recchia A,Perani L,Sartori D,et al.Site-specific integration of functional transgenes into the human genome by adeno/AAV hybrid vectors.Mol Ther,2004,10 (4):660~670
  • 5Bartlett J S,Kleinschmidt J,Boucher R C,et al.Targeted adeno-associated virus vector transduction of nonpermissive cells mediated by a bispecific F(ab'gamma)2 antibody.Nat Biotechnol,1999,17 (2):181~186
  • 6Ponnazhagan S,Mahendra G,Kumar S,et al.Conjugate-based targeting of recombinant adeno-associated virus type 2 vectors by using avidin-linked ligands.J Virol,2002,76 (24):12900~12907
  • 7Yang Q,Mamounas M,Yu G,et al.Development of novel cell surface CD34-targeted recombinant adenoassociated virus vectors for gene therapy.Hum Gene Ther,1998,9 (13):1929~1937
  • 8Wu P,Xiao W,Conlon T,et al.Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism.J Virol,2000,74 (18):8635~8647
  • 9Girod A,Ried M,Wobus C,et al.Genetic capsid modifications allow efficient retargeting of adeno-associated virus type 2.Nat Med,1999,5 (9):1052~1056
  • 10Grifman M,Trepel M,Speece P,et al.Incorporation of tumor-targeting peptides into recombinant adeno-associated virus capsids.Mol Ther,2001,3 (6):964~975

共引文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部